UK markets closed

CureVac N.V. (CVAC)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
19.48+0.62 (+3.32%)
As of 03:52PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close18.85
Open18.85
Bid19.56 x 1800
Ask19.59 x 1000
Day's range18.61 - 19.67
52-week range14.20 - 125.66
Volume434,660
Avg. volume529,961
Market cap3.644B
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-2.37
Earnings date15 Aug 2022 - 19 Aug 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est27.69
  • Simply Wall St.

    CureVac (NASDAQ:CVAC) Is In A Good Position To Deliver On Growth Plans

    Just because a business does not make any money, does not mean that the stock will go down. For example, although...

  • EQS Group

    CureVac Announces Financial Results for the First Quarter of 2022 and Provides Business Update

    Issuer: CureVac / Key word(s): Quarter Results25.05.2022 / 13:05 The issuer is solely responsible for the content of this announcement.CureVac Announces Financial Results for the First Quarter of 2022 and Provides Business Update Progressing broad vaccine development program in collaboration with GSK, with second-generation candidates in Phase 1 clinical trials for COVID-19 and influenza CureVac eligible to a €10 million milestone payment from GSK for the initiation of the influenza clinical tri

  • EQS Group

    CureVac Partners with myNEO to Identify Novel Antigen Targets for mRNA-Based Cancer Vaccine Development

    Issuer: CureVac / Key word(s): Alliance25.05.2022 / 13:00 The issuer is solely responsible for the content of this announcement.CureVac Partners with myNEO to Identify Novel Antigen Targets for mRNA-Based Cancer Vaccine Development CureVac is broadening its foundation in oncology, leveraging recent progress with its second-generation mRNA backbone The partnership combines CureVac’s mRNA technology with myNEO’s platform for the discovery and selection of tumor antigens predicted to elicit strong